This work proposes integrating exosome engineering and senolytic strategies to lay the foundation for early diagnosis and precision therapy of Parkinson's disease, promoting diagnosis-intervention translational research and bridging bench-tobedside translation.
Abstract
ABSTRACT
Parkinson's disease is characterized by α-synuclein aggregation, dopaminergic neuron loss, and neuroinflammation. Emerging evidence reveals complex crosstalk between exosomes and cellular senescence in Parkinson's disease pathogenesis. Exosomes mediate α-synuclein transmission and neuroinflammation, while delivering protective factors such as miRNAs that inhibit cellular senescence. Senescent cells secrete pro-inflammatory factors via mitochondrial dysfunction and the senescence-associated secretory phenotype, linking to Parkinson's disease mitophagy defects. This forms a vicious "senescence-protein deposition-inflammation" cycle, with senescent cell-derived exosomes exacerbating α-synuclein aggregation and inflammation. Therapeutically, exosomes are ideal drug carriers due to blood-brain barrier penetrability and low immunogenicity for targeted antioxidant delivery. Future perspectives highlight exosome-based biomarkers and brain-gut axis intervention as promising directions. We propose integrating exosome engineering and senolytic strategies to lay the foundation for early diagnosis and precision therapy of Parkinson's disease, promoting diagnosis-intervention translational research and bridging bench-tobedside translation.
Immunosenescence represents a core upstream driver of Alzheimer's disease (AD) and Parkinson's disease (PD), exerting its pathological effects through four mechanistically interconnected cascades: chronic inflammatory imbalance mediated by the senescence-associated secretory phenotype (SASP), oxidative stress arising f...
Overall, postbiotics may represent a promising therapeutic strategy for targeting neurodegenerative processes in PD, although their safety, efficacy, optimal dosing, and clinical utility require further investigations.
Anjali Kumari, K. Aran· Metabolic brain disease· 0 citations
This review focuses on translational insights linking α-syn pathology to dysregulated stress-response and protein quality-control pathways, intending to identify potential targets for disease-modifying intervention.
Swaprakash Paul, Abhideep Roy, Pallab Bhattacharya et al.· Current Pharmacology Reports· 0 citations
The natural flavonoid Astragalin concurrently addresses three core pathological processes in PD, namely dopaminergic neuron degeneration, α-synucleinopathy, and neuroinflammation, through coordinated modulation of interconnected molecular pathways.
Jun Wang, Jie-Yu He, Qin Huang et al.· Free Radical Biology & Medic...· 0 citations
This review summarizes the regulatory mechanisms of the Keap1-Nrf2 pathway and evaluates how its activation counteracts core PD pathologies, and highlights the extensive crosstalk between Nrf2 and other major signaling networks that collectively determine dopaminergic neuronal survival.